. Each RNA sequence (AF83-1 and AF83-2 to AF83-23) is labeled with biotin at the 5′-end using the Biotin-TEG phosphoramidite (Glen Research). AF83-1 is the known aptamer sequence that binds to VEGF 165 Supplementary Table 3 (ST-3) . Association was monitored for 300 sec and the dissociation was followed for 300 sec on a FortéBio Octet Red 96 instrument. The data were fit to a 1:1 binding model using FortéBio Octet data analysis software. 165 . A stock of 50.0 nM VEGF 165 in PBST buffer (10 mM Sodium phosphate, 150 mM NaCl, 0.04% Tween 20, pH 7.4) was prepared as a dilution series (0, 1.0, 2.0, 3.0, 4.0, 6.0 nM). Association was monitored for 300 sec and the dissociation was followed for 300 sec on a FortéBIO Octet Red 96 instrument. The dissociation was stretched to at least 1,000 sec to verify tight binding. The data were fit to a 1:1 binding model using fortéBIO Octet data analysis software. Kinetic constants were determined by integration of the experimental data using the differential rate equation dR/dt = k on ·C·(R max -R)-k off ·R to obtain both the diffracted to 1.9 Å resolution. Electron density maps generated from initial phases obtained by molecular replacement using α-thrombin without RNA from the crystal structure of the native complex (PDB ID code 3DD2) readily revealed the aptamer and positive difference electron density around the 2′-substituent of two 2′-SeMe-modified ribonucleotides confirmed the correct orientation of the aptamer. Selected crystal data, X-ray data collection, and refinement statistics are listed in Supplementary Table 5 . The final model contains the entire 25-nucleotide aptamer, thrombin light-chain (L) residues 4L through 36L and heavy-chain (H) residues 1H through 258H, the PPACK inhibitor, 163 water molecules, and one magnesium and one calcium ion. In addition, Asn-53 was found to be modified with an N-acetyl-Dglucosamine moiety. Overall views of the aptamer-thrombin complex are depicted in here.
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